Filtros de búsqueda

Lista de obras de

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

artículo científico publicado en 2012

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

artículo científico publicado en 2017

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

artículo científico publicado en 2008

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

artículo científico publicado en 2008

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

artículo científico publicado en 2008

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis

artículo científico publicado en 2020

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

artículo científico publicado en 2014

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

artículo científico publicado en 2017

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia

artículo científico publicado en 2009

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

scientific article published on 30 July 2018

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma

artículo científico publicado en 2017

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda